Literature DB >> 26940147

Canadian women's attitudes toward noninvasive prenatal testing of fetal DNA in maternal plasma (.).

Gali Pariente1, Lara Hasan2, Yifat Gadot1, Leanne R De Souza1, Gerald Lebovic3,4, Howard Berger1,4,5.   

Abstract

OBJECTIVE: To determine the perceptions and attitudes of Canadian women to Noninvasive Prenatal Testing of fetal DNA. STUDY
DESIGN: A designed questionnaire was administered to women attending the outpatient antenatal clinic at a tertiary urban hospital. Attitudes to current and new prenatal screening modalities were assessed using a five-point Likert scale. Bowker's test of symmetry was used to compare individual responses regarding the two screening modalities. Changes in women's responses pre- and post-delivery were also compared.
RESULTS: One hundred and twenty-nine women were enrolled in this study. 88% of women state that they would perform prenatal screening via fetal DNA in the maternal plasma if available. When compared to conventional screening, significantly less women believe that the NIPT should be available upon request for non-medical traits (36.4% versus 60.4%, p < 0.001). When compared to their answer before delivery, more women agreed that screening with fetal DNA in maternal plasma could be used in a negative way to select for desired non-medical traits such as gender.
CONCLUSIONS: The use of fetal DNA in the maternal plasma is widely accepted in our Canadian population as a future method of noninvasive prenatal screening despite recognition of certain ethical concerns. This information can be used when implementing new genetic screening programs.

Entities:  

Keywords:  Fetal aneuploidy; perception; prenatal diagnosis; screening

Mesh:

Substances:

Year:  2016        PMID: 26940147     DOI: 10.3109/14767058.2016.1152253

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  1 in total

1.  Not-so-free testing for cell-free DNA.

Authors:  Darryl Huang; Karen Lundgard; Michael R Kolber
Journal:  Can Fam Physician       Date:  2016-10       Impact factor: 3.275

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.